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Abstract
 
Osteopontin (OPN) is abundantly expressed in human calcified arteries. To examine the role
of OPN in vascular calcification, OPN mutant mice were crossed with matrix Gla protein
(MGP) mutant mice. Mice deficient in MGP alone (MGP
 
 
 
/
 
  
 
OPN
 
 
 
/
 
 
 
) showed calcification
of their arteries as early as 2 weeks (wk) after birth (0.33 
 
  
 
0.01 mmol/g dry weight), and the
expression of OPN in the calcified arteries was greatly up-regulated compared with MGP
wild-types. OPN accumulated adjacent to the mineral and colocalized to surrounding cells in
the calcified media. Cells synthesizing OPN lacked smooth muscle (SM) lineage markers, SM
 
 
 
-actin and SM22
 
 
 
. However, most of them were not macrophages. Importantly, mice defi-
cient in both MGP and OPN had twice as much arterial calcification as MGP
 
 
 
/
 
  
 
OPN
 
 
 
/
 
  
 
at 2
wk, and over 3 times as much at 4 wk, suggesting an inhibitory effect of OPN in vascular cal-
 
cification. Moreover, these mice died significantly earlier (4.4 
 
  
 
0.2 wk) than MGP
 
 
 
/
 
  
 
OPN
 
 
 
/
 
 
 
counterparts (6.6 
 
  
 
1.0 wk). The cause of death in these animals was found to be vascular rup-
ture followed by hemorrhage, most likely due to enhanced calcification. These studies are the
first to demonstrate a role for OPN as an inducible inhibitor of ectopic calcification in vivo.
Key words: biomineralization • gene knockout • phenotype transition • smooth muscle cells • 
vessel rupture
 
Introduction
 
Vascular calcification is widespread in individuals with ath-
erosclerosis, diabetes mellitus, and chronic renal failure. It
occurs at two histological sites of arteries: intima, where it
is commonly associated with atheromas and complicated
lesions of atherosclerosis (1, 2), and media, where Möncke-
berg’s sclerosis forms, such as calcification of coronary ar-
tery in type I diabetic patients (2, 3). Epidemiological stud-
ies have shown that vascular calcification, determined by
electron beam computed tomography, is positively corre-
lated with atherosclerotic plaque burden and increased risk
of myocardial infarction (1, 4–6), increased ischemic epi-
sodes in peripheral vascular disease (7), and increased mor-
bidity after angioplasty (8). Using autopsy specimens, calci-
fication was found to be a reliable marker of plaque
instability, defined as plaques that have undergone rupture
(9). Moreover, in a recent study of 79 sudden cardiac death
cases, both the Framingham risk index and coronary calcifi-
cation were demonstrated to be predictive of future cardio-
vascular events (10).
Mechanisms regulating vascular calcification are currently
under investigation. Morphological studies have shown
that pathological calcification of blood vessels shares fea-
tures with normal embryonic bone formation and bone re-
pair. Matrix vesicles, postulated nucleation sites for the for-
mation of apatite mineral in cartilage and perhaps bone,
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have been detected in calcified atherosclerotic lesions (11,
12). Furthermore, proteins involved in the regulation of
skeletal bone formation have also been found to be present
in human atherosclerotic lesions. These proteins include
osteoprotegerin and its ligand, bone sialoprotein, bone
morphogenetic protein (BMP)
 
*
 
-2 and BMP-4, osteocalcin,
osteonectin, matrix Gla protein (MGP), and osteopontin
(OPN; 13–17).
OPN is an acidic, phosphorylated glycoprotein that was
first discovered in bone and is thought to be involved in
the regulation of biomineralization by promoting osteoclast
function through the 
 
 
 
v
 
 
 
3 
 
integrin and by inhibiting apatite
crystal growth (18, 19). Although OPN is not present in
most normal soft tissues, it is abundant at sites of ectopic
calcification in human atherosclerotic lesions (20–25), dia-
betic arteries (26), uremic arteriolopathy (27), and in native
and prosthetic valves (28–31). In calcified arteries and
valves, OPN is highly localized to the surfaces of calcified
deposits (32, 33). The colocalization of OPN with calcified
deposits and the finding that OPN potently inhibits cal-
cium deposition in calcifying smooth muscle cells (SMCs)
in vitro (34) suggests a role for OPN in regulating vascular
calcification in vivo, although OPN-deficient mice do not
have a mineralization defect per se.
Because OPN is not expressed in normal blood vessels
but only appears under pathological conditions, we used
MGP mutant mice that spontaneously develop vascular
calcification (35) as a model of vascular injury. To delin-
eate the function of OPN in vascular calcification in vivo,
we crossed OPN mutant mice with MGP mutants and ex-
amined the arteries of the double mutant mice. We found
that the inactivation of the OPN gene in MGP knockout
mice significantly enhanced vascular calcification, indicat-
ing that OPN may act during an adaptive response as an
inducible inhibitor.
 
Materials and Methods
 
Generation of MGP and OPN Knockout Mice.
 
MGP mutant
mice were generated in a C57BL/6J background as previously
described (35). OPN mutant mice were generated in a 129/
SvJ 
 
  
 
Black Swiss background (36). The hybrid OPN mutant
mice were backcrossed with Black Swiss for 7 generations followed
by inbreeding for 
 
 
 
13 generations. Animals were maintained in a
specific pathogen-free environment, fed standard chow and water
ad libitum, and their genotypes were determined as previously
described (35, 36). To generate mice deficient in both MGP and
OPN (MGP
 
 
 
/
 
  
 
OPN
 
 
 
/
 
 
 
), MGP heterozygotes (MGP
 
 
 
/
 
 
 
) were
crossed with OPN homozygous null mice (OPN
 
 
 
/
 
 
 
) to generate
MGP and OPN heterozygotes (MGP
 
 
 
/
 
  
 
OPN
 
 
 
/
 
 
 
). These F1
mice were used as breeders to generate nine groups of mice car-
rying different genotypes (F2), including MGP
 
 
 
/
 
  
 
OPN
 
 
 
/
 
  
 
and
MGP
 
 
 
/
 
 
 
OPN
 
 
 
/
 
 
 
. The F2 offspring were killed by giving a lethal
intraperitoneal injection of nembutol (0.3 mg/g mouse) at indi-
cated ages for necropsy. Animals used in these studies were on a
 
C57BL/6 
 
  
 
Black Swiss hybrid background. 295 mice were ex-
amined in the studies. All protocols were approved by the Animal
Use Committee, University of Washington, Seattle, WA.
 
Tissue Preparation and Immunohistological Analysis of Aortas of
MGP 
 
  
 
OPN Mutant Mice.
 
Aortas dissected from MGP 
 
 
 
OPN mutant mice were fixed in methyl Carnoys fixative (meth-
anol/acetic acid, 3:1) for 24 h and embedded in paraffin. 5-
 
 
 
m
sections were used for histochemical and immunohistochemical
analysis. Hematoxylin and eosin staining was used for histology.
Alizarin red S (0.5%, pH 9.0; Sigma-Aldrich) and Von Kossa
staining were used to detect calcification. For immunohis-
tochemical staining, sections were first blocked with biotin and
avidin blocking reagents (Vector Laboratories) and PBS contain-
ing 0.25% bovine serum albumin and 4% serum (same species as
that of secondary antibody produced). Polyclonal goat anti–OPN
antibody (OP199) was used to determine OPN expression (37).
Monoclonal mouse anti–smooth muscle (SM) 
 
 
 
-actin antibody
(1A4; Sigma-Aldrich) and polyclonal rabbit anti–SM22
 
  
 
anti-
body (provided by M. Parmacek, University of Pennsylvania,
Philadelphia, PA) were used to identify SMCs. Polyclonal rat
anti–murine pan macrophage antibody (BM-8; Accurate Chemi-
cal & Scientific Corp.) was used to identify macrophages. After
incubation at room temperature for 1 h, the sections were in-
cubated with biotinylated secondary antibodies (Vector Labo-
ratories) before streptavidin-conjugated peroxidase staining or
fluorophore-conjugated secondary antibodies. Sections were
counterstained with methyl green (2% methyl green, 2% pyronin
Y; Sigma-Aldrich).
To quantitate the expression of vascular OPN and SM 
 
 
 
-actin
in MGP 
 
  
 
OPN mutant mice, immunohistochemically stained
sections were photographed at low magnification using a phase-
contrast microscope equipped with an epi-differential interfer-
ence contrast system and a digital camera. Positively stained areas
of the whole vessel were quantitated with MetaMorph image
analysis software using an identical level of color threshold. The
expression of SM 
 
 
 
-actin and OPN are expressed as a percentage
of the whole vessel wall and averaged from at least four sections
per sample.
 
Quantitative Analysis of OPN by ELISA.
 
Maxisorp plates
(Nunc) were coated overnight at room temperature with soluble
goat anti–mouse OPN antibody (AF808; R&D Systems). The
plates were blocked with PBS containing 2% bovine serum albu-
min and 1.5% normal goat serum, and mouse sera were added to
the plate. After incubation at room temperature for 2 h, AF808-
bound OPN was detected with a polyclonal rabbit anti–human
OPN antibody (LF123; provided by L.W. Fisher, National Insti-
tutes of Health [NIH], Bethesda, MD) before incubation with bio-
tinylated anti–rabbit antibody and streptavidin-conjugated perox-
idase staining.
 
Calcium Quantification.
 
Tissues were lyophilized to constant
weight and decalcified with 0.6 mmol/L HCl at 37
 
 
 
C for 24 h.
Calcium released from the lyophilized tissues was determined
colorimetrically by the o-cresolphthalein complex one method as
previously described (calcium diagnostic kit; Sigma-Aldrich; ref-
erence 38). The amount of vascular calcium was normalized to
the dry weight of the tissues and expressed as millimolar/gram
dry weight.
 
High Resolution X-ray Microcomputed Tomography.
 
Isolated
aortas from MGP 
 
  
 
OPN mutant mice were scanned nonde-
structively on a microcomputed tomography system (
 
 
 
CT 40;
Scanco Medical) at a voxel resolution of 16 microns. Recon-
structed image slices were stacked to create 3D images of calcified
regions within the aortas. The average thickness of the calcified
 
*
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BMP, bone morphogenetic protein;
MGP, matrix Gla protein; OPN, osteopontin; SM, smooth muscle;
SMC, smooth muscle cell. 
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region within the aortic wall was measured using direct 3D mor-
phometric analysis (39).
 
Statistical Analysis.
 
Data, shown as means 
 
  
 
SEM, were ana-
lyzed with Student’s 
 
t 
 
test or analysis of variance to determine the
significance of differences. The association of two variables,
shown as correlation coefficient, was considered statistically sig-
nificant at a P value of 
 
 
 
0.05. The differences between observed
data and expected data were analyzed by 
 
 
 
2 
 
test and considered to
be statistically significant at a P value of 
 
 
 
0.05.
 
Results
 
Crossing of MGP Mutant Mice with OPN Mutant Mice.
 
As reported previously (35), MGP null homozygotes
showed ectopic arterial calcification (which led to vessel
rupture), cartilage calcification (which led to short stature),
osteopenia, and fracture. MGP heterozygotes showed no
ectopic calcification. OPN null homozygotes and het-
erozygotes developed normally and were grossly normal at
birth, with no overt evidence of bone or vascular defects
under normal conditions (16, 36).
To examine whether endogenous OPN might be in-
volved in vascular calcification under conditions of MGP
deficiency, we crossed MGP mutant mice with OPN mu-
tant mice, as described in Materials and Methods. Analysis
of 295 F2 mice showed that the frequency of nine different
genotypes was close to the expected Mendelian ratio (
 
 
 
2
 
 
 
 
 
4.58, P 
 
  
 
0.250), indicating no embryological lethality.
However, mice carrying genotypes of MGP
 
 
 
/
 
  
 
OPN
 
 
 
/
 
 
 
,
MGP
 
 
 
/
 
  
 
OPN
 
 
 
/
 
 
 
, MGP
 
 
 
/
 
  
 
OPN
 
 
 
/
 
 
 
, and MGP
 
 
 
/
 
 
 
OPN
 
 
 
/
 
  
 
started to die during weeks 3 and 4 after birth. By
analyzing the average death ages of mice of different geno-
types, a profound effect of OPN on the postnatal survival
of MGP
 
 
 
/
 
  
 
mice was observed. Mice deficient in both
MGP and OPN had an average death age of 4.4 
 
  
 
0.2 wk,
whereas MGP null mice with a wild-type OPN gene had
an average death age of 6.6 
 
  
 
1.0 wk (
 
n
 
 
 
  
 
5 
 
  
 
9/geno-
type, P 
 
  
 
0.05). Similar to the MGP
 
 
 
/
 
  
 
mice, vascular
rupture followed by hemorrhage most likely due to severe
vascular calcification, was found to be the cause of death in
these animals.
 
OPN Is an Inducible Inhibitor of Vascular Calcification in
MGP Mutant Mice.
 
The expression of OPN in vessels
from MGP 
 
  
 
OPN mutant mice was determined immu-
nohistochemically. As shown in Fig. 1, OPN was abundant
in calcified vessels of MGP
 
 
 
/
 
  
 
OPN
 
 
 
/
 
  
 
mice, but not in
MGP
 
 
 
/
 
  
 
OPN
 
 
 
/
 
  
 
and MGP
 
 
 
/
 
  
 
OPN
 
 
 
/
 
  
 
arteries (A). At a
higher magnification (Fig. 1, B and C), OPN was found
coating mineral deposits (arrows) and it also colocalized to
some cells of the calcifying medial layer (arrowheads).
Quantitative analysis of the immunohistochemical images
showed an age-dependent increase of OPN expression in
MGP
 
 /  OPN /  mice (Fig. 1 D). In addition, serum
OPN was determined by ELISA and was found to be in-
creased, to a smaller degree, in MGP /  OPN /  mice
compared with wild-types (1.5   0.14  g/ml vs. 1.0  
0.04  g/ml; n   3   7, P   0.01), but completely absent
in MGP /  OPN /  mice.
To determine the effect of OPN on arterial calcification,
we examined aortas and carotid arteries from MGP  
OPN mutant mice. As shown in Fig. 2, aortas from mice
deficient in MGP alone were calcified as early as 2 wk after
birth and calcification increased with age. Interestingly,
aortas from mice deficient in both MGP and OPN had al-
most twice as much calcification as MGP /  OPN /  at 2
wk (0.61    0.06 mmol/g dry weight vs. 0.33    0.01
mmol/g dry weight) and over three times as much at 4 wk
(2.02   0.07 mmol/g dry weight vs. 0.62   0.06 mmol/g
dry weight). Moreover,  30% of MGP /  OPN /  mice
(8 out of 25) showed overt vascular calcification at 4–8 wk,
whereas MGP /  OPN /  mice never showed vascular
calcification at any time point observed.
As shown in Fig. 3, calcification of arteries from MGP  
OPN mutant mice was visualized in cross sections by Al-
izarin red S (A, red, asterisks) and Von Kossa (B, dark
brown, asterisks), and in a 3D reconstruction of a segment
of aorta by microcomputed tomography (C, gray, asterisks).
A similar overall morphology of arterial calcification was
observed in all calcifying genotypes. Calcification was
mainly located in the arterial media and in the early stages
was associated with elastic lamina (Fig. 3 D, asterisks). As the
process proceeds, fully mineralized media, mild to moderate
intimal and medial thickening (Fig. 3 A–C and E, asterisks),
fragmentation of elastic laminae (G, arrows vs. normal elastic
laminae in F), partially dissected arterial wall and rupture (H,
arrowheads), and aneurysm formation (I, arrowheads) were
observed in the calcified vessels. Taken together, these re-
sults demonstrate that the inactivation of the OPN gene en-
hances the magnitude of vascular calcification of MGP-defi-
cient mice, probably leading to the accelerated mortality.
These studies are the first to validate a role for OPN as an
inducible inhibitor in vascular calcification in vivo.
Correlation of Vascular Calcification with Loss of SM Lineage
Markers in MGP   OPN Mutant Mice. We have previ-
ously reported a novel association of vascular calcification
with SMC phenotypic transition, i.e., up-regulation of
Cbfa1 and down-regulation of SM lineage markers (40). In
this study of MGP   OPN mutant mice, we were able to
analyze this association in greater detail. As shown in Fig. 4,
arteries from wild-type animals showed no calcification (A)
and were strongly stained for SM lineage marker, SM  -actin
(D), as expected. When the arteries were partially calcified, as
shown in 2-wk-old MGP /  OPN    mice (Fig. 4 B), vas-
cular  -actin was retained only in the areas that had not yet
undergone calcification, but not in the calcified areas (E).
When the arteries were extensively calcified (Fig. 4 C), a
complete loss of SM  -actin expression was observed (F).
Statistical analysis of 38 mice for the relationship of genotype,
SM  -actin expression, and vascular calcification showed that
SM  -actin expression was negatively correlated with cal-
cium amount of the vessels (Fig. 4 G, r    0.5200, P  
0.001), but not with genotypes (unpublished data). Similar
results were obtained when aortic sections were stained for
SM22 , a second SM-specific marker (unpublished data).
The loss of SM  -actin and SM22  expression in calcified
arteries of MGP   OPN mutant mice is not due to cellular1050 Osteopontin Inhibits Vascular Calcification In Vivo
deficiency, as counterstaining of the sections with methyl
green (Fig. 4 B, C, E, and F) and adjacent sections stained
with hematoxylin and eosin (unpublished data) showed nu-
merous nuclei in the calcified area. Moreover, cells positively
stained for SM lineage markers were observed in noncalcified
areas (Fig. 4 E, arrowheads) and in the small adventitial ves-
sels of extensively calcified arteries (F, arrowheads).
Figure 1. OPN expression in the calcified aortas of MGP   OPN mu-
tant mice. (A) Aortas of 2-wk-old MGP /  OPN /  and MGP / 
OPN /  mice, and their wild-type counterparts were examined immu-
nohistochemically for OPN expression. Arrows and arrowheads indicate
OPN expressed in the arterial wall. Open arrows indicate mineral deposi-
tion in the MGP /  OPN /  aortas, as determined by Alizarin red S
staining of adjacent section (not depicted). (B and C) Double staining of
aorta of a 6-wk-old MGP /  OPN /  mouse by immunohistochemistry
for (B) OPN expression and by (C) Alizarin red S for mineral deposition.
Note the association of OPN with mineral (arrows) and cells in the min-
eralized area (arrowheads). L, lumen; M, media; Ad, adventitia; *, min-
eral. (D) OPN expression in aortas of mice carrying different genotypes
was quantified by MetaMorph image analysis as described in Materials and
Methods. Data shown are mean   SEM, n   4   10.
Figure 2. Quantification of calcium amount in vessels of MGP   
OPN    and MGP    OPN    mice. 2- and 4-wk-old mice with indi-
cated genotypes were killed by nembutal and their aortas were dissected
and lyophilized. Calcium content of the lyophilized vessels was deter-
mined using a Sigma-Aldrich calcium diagnostic kit as described in Mate-
rials and Methods. Data shown are mean   SEM, n   4   9, F   106.5,
P   0.0001 (analysis of variance).1051 Speer et al.
Vascular Cells, But Not Macrophages, Are the Predominant
Cells Synthesizing OPN. As shown in Fig. 1 B, cells in the
calcifying medial layer of MGP mutant mice synthesized
OPN. To further characterize these cells, arteries dissected
from MGP mutant mice were stained immunohistochemi-
cally for SMCs, the predominant cells of the arterial wall,
and macrophages, the inflammatory cells reported to be
present in human calcified vessels and synthesize OPN (22).
As we have shown in Fig. 4 and in the previous report (40),
SMCs in the calcified area lost their lineage marker, SM
 -actin and SM22 , and gained expression of OPN. To
determine whether these cells were macrophages, antibodies
to BM8, a macrophage-specific surface marker, were used
in immunohistochemistry. As shown in Fig. 5, there were
no macrophages present in normal arteries of wild-type ani-
mals (A). However, at 2 wk, when arteries were slightly cal-
cified (Fig. 5 C), immunostained macrophages appeared ex-
clusively in the adventitial layer (B, arrows). At 4 wk, when
calcification was widespread, some macrophages infiltrated
into the media surrounding calcium deposits (unpublished
data). Using double immunohistochemical staining (Fig. 5,
D–F), although macrophages were found to synthesize
OPN (arrows), the predominant cells expressing OPN in
the calcified arteries were found in the medial layer where
macrophages were absent (open arrows). Taken together,
these data indicate that the major source of OPN in the
calcified arteries of MGP mutant mice are vascular medial
cells, most likely SMCs that had undergone phenotypic
transition and some macrophages that had infiltrated into
the media.
Discussion
OPN is highly expressed in the calcified lesions of hu-
man primary and restenotic atherosclerosis (20, 22, 41), di-
abetes (26), and chronic renal failure (27) although little is
Figure 3. Representative histological analyses and
microcomputed tomography of calcified arteries. (A–
C) Aortic mineralization of 4-wk-old MGP /  OPN / 
mice was visualized by (A) Alizarin red S, (B) Von
Kossa, and (C) microcomputed tomography. The aver-
age thickness of the calcified region for three aortas
from 4-wk-old MGP /  OPN /  mice was 92.2  
26.4 microns. (D–I) Histological analyses of calcified
arteries: (D and E) Von Kossa staining, (F–H) Hema-
toxylin and eosin staining, and (I) Alizarin red S stain-
ing. Note (G) elastic laminae fragmentation (arrows),
(H) vessel rupture (arrowheads), and (I) aneurysm for-
mation (arrowheads). L, lumen; M, media; Ad, adven-
titia; *, mineral.1052 Osteopontin Inhibits Vascular Calcification In Vivo
known about its role in these lesions. In this study, we have
demonstrated for the first time the inhibitory effect of
OPN on vascular calcification in vivo. Using MGP mutant
mice as a vascular calcification model, endogenous OPN
expression was found to be dramatically up-regulated in
cells of the arterial media where ectopic mineralization had
formed. Concomitant with the gain of OPN expression,
the expression of SM lineage markers, SM  -actin and
Figure 4. SMCs in calcified arteries lose their lineage marker, SM  -actin. (A–C) Aortas of 2-
and 4-wk-old MGP   OPN mutant mice were examined for mineral deposition by Von Kossa
staining (arrows) and (D–F) for SM  -actin by immunohistochemistry (arrowheads). Note the loss
of SM  -actin in the mineralized area of aortas from (E) 2-wk and (F) 4-wk MGP /  OPN / 
mice. L, lumen; M, media; Ad, adventitia. (G) Correlation of aortic SM  -actin expression and cal-
cium deposition. SM  -actin expression in the aortas of MGP   OPN mutant mice was quantified
by MetaMorph image analysis of the stained sections and the corresponding vascular calcium depo-
sition by determining the acid-released calcium using a Sigma-Aldrich calcium diagnostic kit as de-
scribed in Materials and Methods. n   38, P   0.001.
Figure 5. Macrophages are not
the predominant cells to synthesize
OPN in calcified aortas of MGP  
OPN mutant mice. (A and B) Aortas
of 2-wk-old MGP   OPN mutant
mice were stained immunohis-
tochemically for macrophages using
streptavidin-conjugated peroxidase.
Note the recruitment of macro-
phages into (B) adventitia of calcified
arteries (arrows), but not in (A) nor-
mal vessels. (C) Adjacent section
stained for mineral (arrowheads) by
Von Kossa. Colocalization of mac-
rophages and OPN was further de-
termined by double immunohis-
tochemical staining using
fluorophore-conjugated secondary
antibodies. (D) Rhodamine-OPN,
(E) Cyanine-BM8, and (F) Overlay
of D and E onto a differential interference contrast photo of the same field. Note OPN  cells (red in D and red and yellow in F) were present mostly in
the medial layer where macrophages (green in E and green and yellow in F) were absent. Arrows, macrophages; open arrows, OPN-expressing cells ex-
cept macrophages; arrowheads, mineral; L, lumen; M, media; Ad, adventitia; *, internal and external elastic laminae.1053 Speer et al.
SM22 , declined substantially in calcified arteries. Cells
synthesizing OPN were found to be mainly vascular medial
cells, most likely SMCs that had undergone phenotypic
transition and in a lower percentage, infiltrated macro-
phages. Furthermore, in comparison with mice deficient in
MGP alone (MGP /  OPN / ), mice lacking both MGP
and OPN (MGP /  OPN / ) showed accelerated and en-
hanced medial calcification. The enhanced calcification
correlated with decreased survival of the mice, most likely
due to increased vessel rupture and hemorrhage. Finally, al-
though MGP /  OPN /  mice never showed calcification,
 30% of MGP /  OPN /  mice had calcified arteries.
Taken together, these observations demonstrate for the first
time an adaptive mechanism by which OPN serves as an
important inducible mediator to inhibit vascular calcifica-
tion in vivo.
Vascular calcification is an actively regulated process that
may involve chondrogenic and/or osteogenic differentia-
tion of vascular cells and the expression of bone-related
mediators and inhibitors. Support for the concept of active
regulation of vascular calcification is best exemplified by
the occurrence of vascular calcification in the MGP null
mouse. MGP is a small matrix protein originally found in
developing bone (42). It contains several  -carboxy-
glutamic acid residues (Gla residues), most of which are
clustered centrally in the protein, providing a negatively
charged region for the protein to bind to hydroxyapatite
(42–44). In normal blood vessels, the protein is secreted by
SMCs and binds to elastic laminae of the tunica media and
the extracellular matrix of the adventitia, and in calcified
vessels, the protein accumulates at the interface between
mineralized and nonmineralized areas (45, 46).
Although the mechanism by which MGP inhibits vascu-
lar calcification is not yet known, several possibilities have
been posited. First, MGP may act as a calcification “surveil-
lance” inhibitor by binding to small calcium phosphate
precipitates and removing them via the circulation, thus
preventing the vessels from becoming mineralized (47–49).
In support of this, rats treated with the bisphosphonate
etidronate, showed elevated serum levels of a protein–min-
eral complex consisting of calcium, phosphate, fetuin, and
MGP (47). Alternatively, MGP may normally prevent in-
appropriate differentiation within the blood vessel because
it was recently reported to be an inhibitor of BMP-2, a fac-
tor promoting osteogenic and chondrogenic differentiation
(50). Finally, MGP may inhibit vascular calcification via di-
rect interaction with putative nucleating sites in the elastic
lamina, as these structures are the preferred sites for initia-
tion of mineral deposition in the MGP null mouse as well
as in warfarin-treated rats and Mönckeberg’s medial sclero-
sis (35, 45, 51, 52).
OPN, on the other hand, is not constitutively expressed
in blood vessels, but rather is induced by various injurious
stimuli (32). Indeed, OPN was only expressed in calcified
vessels of the MGP mutant mice. Thus, OPN appears to
function as an inducible “damage control” inhibitor of cal-
cification. The mechanism by which OPN inhibits miner-
alization is also unclear, but physical inhibition of apatite
deposition and accumulation is likely. OPN has a high
content of aspartic acid residues and is highly phosphory-
lated on serine and threonine residues. This structure en-
ables OPN to bind to hydroxyapatite and calcium ions, and
thus to physically inhibit crystal formation and growth in
vitro (19, 53, 54). Consistent with these in vitro findings,
the OPN localized in the calcified arteries of MGP /  mice
in this study was found to be closely associated with min-
eral, predominantly accumulating on the mineral surface as
a dense planar coating (Fig. 1 B) and therefore potentially
acting locally to inhibit mineral growth via a direct physical
interaction. Because the OPN null mice do not show vas-
cular calcification, it is unlikely that OPN generally regu-
lates SMC phenotype. However, we cannot rule out the
possibility that lack of OPN, in the context of MGP defi-
ciency, effects the differentiation and subsequent mineral-
ization potential of vascular SMCs, as discussed below.
We and others have previously shown that cultured hu-
man and bovine medial SMCs have the ability to mineral-
ize their matrices under defined culture conditions (34, 38,
55). The calcifying SMCs were further characterized to
have undergone phenotypic transition to Cbfa1 , osteo-
chondroprogenitor-like cells (40). These cells lost their SM
lineage markers but gained Cbfa-1 expression, a factor re-
quired for osteogenesis and chondrocyte hypertrophy, and
expressed genes containing the Cbfa1 binding site OSE2,
including OPN, osteocalcin, and alkaline phosphatase (40,
46, 55–57). Moreover, the addition of exogenous OPN to
cultured calcifying SMCs inhibited their ability to calcify
the matrices in a dose-dependent manner (34). The ability
of OPN to inhibit calcification of SMC cultures was later
found to depend entirely on a posttranslational modifica-
tion, phosphorylation of the protein (54).
In this study, vascular SMCs in the mineralized area of
MGP-deficient mice were also found to have lost their lin-
eage markers SM  -actin and SM22 , and the cells in the
calcified areas, most likely phenotypically modified SMCs,
were found to produce OPN. Thus, vessels undergoing
mineralization appear to adapt the loss of MGP by up-regu-
lating a potent inhibitor of mineralization, namely OPN.
Furthermore, the ability to up-regulate OPN extends a sur-
vival advantage to mice. Whether endogenously produced
OPN inhibits vascular calcification of MGP mutant mice via
direct physical inhibition or a decrease in the mineralizing
potential of medial SMCs is currently under investigation.
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